New Athira Pharma Drug Trial for Parkinson’s, with Dr. Arif Khan

Dr. Arif Khan at the Northwest Clinical Research Center talks about Parkinson’s disease and an exciting clinical study by Athira Pharma for the treatment of Parkinson’s Disease Dementia (PDD) and Dementia with Lewy Bodies. The medicine is designed to boost a repair and regenerative pathway for brain cells, promoting brain health and function. It’s a new approach, potentially targeting the root cause of memory decline by repairing brain cells and rebuilding brain networks. For more information, or to enroll, visit Dr. Khan is a Board Certified Psychiatrist, an Adjunct Professor of Psychiatry at Duke University School of Medicine and an Adjunct Professor of Clinical Medicine at the Pacific Northwest University of Health Sciences. Dr. Khan has been conducting clinical trials in the greater Seattle area since 1984 and founded the Northwest Clinical research Center (NWCRC) in 1995. He has been the Principal Investigator in over 600 clinical trials. In addition, he has published more than 175 scientific papers in leading medical journals. His work on clinical trial design, safety and efficacy is widely recognized and presented at both national and international scientific meetings.